Purging iron from the heart

Chaim Hershko, Maria D. Cappellini, Renzo Galanello, Antonio Piga, Gianni Tognoni, Giuseppe Masera

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Methods are now available to measure the magnitude of iron accumulation in the heart. Their validation currently relies on indirect evidence and not on chemical estimation in cardiac biopsies. All patients with symptomatic heart disease appear to have abnormal T2* values, but many patients without symptomatic heart disease also have evidence of increased myocardial iron. Although there is no proof to date that increased myocardial iron, as evidenced by abnormal magnetic resonance imaging, carries an adverse prognosis, it is likely that such new information will affect the chelating programme of patients. In these cases, there are a number of options available: (i) ongoing treatment with either desferrioxamine (DFO) or deferiprone may be intensified; (ii) the patient may be switched to the alternative chelator or (iii) combined chelation with both DFO and deferiprone may be started, which is more effective than using either chelator alone. For patients with symptomatic heart disease, continuous intravenous DFO with, or without deferiprone, remains the currently recommended treatment, in view of its documented ability to salvage these patients.

Original languageEnglish
Pages (from-to)545-551
Number of pages7
JournalBritish Journal of Haematology
Volume125
Issue number5
DOIs
Publication statusPublished - Jun 1 2004

Fingerprint

Iron
Deferoxamine
Heart Diseases
Chelating Agents
Magnetic Resonance Imaging
Biopsy
Therapeutics
deferiprone

Keywords

  • Deferiprone
  • Desferrioxamine
  • Haemosiderosis
  • Heart
  • Iron chelation

ASJC Scopus subject areas

  • Hematology

Cite this

Hershko, C., Cappellini, M. D., Galanello, R., Piga, A., Tognoni, G., & Masera, G. (2004). Purging iron from the heart. British Journal of Haematology, 125(5), 545-551. https://doi.org/10.1111/j.1365-2141.2004.04946.x

Purging iron from the heart. / Hershko, Chaim; Cappellini, Maria D.; Galanello, Renzo; Piga, Antonio; Tognoni, Gianni; Masera, Giuseppe.

In: British Journal of Haematology, Vol. 125, No. 5, 01.06.2004, p. 545-551.

Research output: Contribution to journalArticle

Hershko, C, Cappellini, MD, Galanello, R, Piga, A, Tognoni, G & Masera, G 2004, 'Purging iron from the heart', British Journal of Haematology, vol. 125, no. 5, pp. 545-551. https://doi.org/10.1111/j.1365-2141.2004.04946.x
Hershko C, Cappellini MD, Galanello R, Piga A, Tognoni G, Masera G. Purging iron from the heart. British Journal of Haematology. 2004 Jun 1;125(5):545-551. https://doi.org/10.1111/j.1365-2141.2004.04946.x
Hershko, Chaim ; Cappellini, Maria D. ; Galanello, Renzo ; Piga, Antonio ; Tognoni, Gianni ; Masera, Giuseppe. / Purging iron from the heart. In: British Journal of Haematology. 2004 ; Vol. 125, No. 5. pp. 545-551.
@article{4360cbb7590a46a0a9f1bbb8b440608b,
title = "Purging iron from the heart",
abstract = "Methods are now available to measure the magnitude of iron accumulation in the heart. Their validation currently relies on indirect evidence and not on chemical estimation in cardiac biopsies. All patients with symptomatic heart disease appear to have abnormal T2* values, but many patients without symptomatic heart disease also have evidence of increased myocardial iron. Although there is no proof to date that increased myocardial iron, as evidenced by abnormal magnetic resonance imaging, carries an adverse prognosis, it is likely that such new information will affect the chelating programme of patients. In these cases, there are a number of options available: (i) ongoing treatment with either desferrioxamine (DFO) or deferiprone may be intensified; (ii) the patient may be switched to the alternative chelator or (iii) combined chelation with both DFO and deferiprone may be started, which is more effective than using either chelator alone. For patients with symptomatic heart disease, continuous intravenous DFO with, or without deferiprone, remains the currently recommended treatment, in view of its documented ability to salvage these patients.",
keywords = "Deferiprone, Desferrioxamine, Haemosiderosis, Heart, Iron chelation",
author = "Chaim Hershko and Cappellini, {Maria D.} and Renzo Galanello and Antonio Piga and Gianni Tognoni and Giuseppe Masera",
year = "2004",
month = "6",
day = "1",
doi = "10.1111/j.1365-2141.2004.04946.x",
language = "English",
volume = "125",
pages = "545--551",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "5",

}

TY - JOUR

T1 - Purging iron from the heart

AU - Hershko, Chaim

AU - Cappellini, Maria D.

AU - Galanello, Renzo

AU - Piga, Antonio

AU - Tognoni, Gianni

AU - Masera, Giuseppe

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Methods are now available to measure the magnitude of iron accumulation in the heart. Their validation currently relies on indirect evidence and not on chemical estimation in cardiac biopsies. All patients with symptomatic heart disease appear to have abnormal T2* values, but many patients without symptomatic heart disease also have evidence of increased myocardial iron. Although there is no proof to date that increased myocardial iron, as evidenced by abnormal magnetic resonance imaging, carries an adverse prognosis, it is likely that such new information will affect the chelating programme of patients. In these cases, there are a number of options available: (i) ongoing treatment with either desferrioxamine (DFO) or deferiprone may be intensified; (ii) the patient may be switched to the alternative chelator or (iii) combined chelation with both DFO and deferiprone may be started, which is more effective than using either chelator alone. For patients with symptomatic heart disease, continuous intravenous DFO with, or without deferiprone, remains the currently recommended treatment, in view of its documented ability to salvage these patients.

AB - Methods are now available to measure the magnitude of iron accumulation in the heart. Their validation currently relies on indirect evidence and not on chemical estimation in cardiac biopsies. All patients with symptomatic heart disease appear to have abnormal T2* values, but many patients without symptomatic heart disease also have evidence of increased myocardial iron. Although there is no proof to date that increased myocardial iron, as evidenced by abnormal magnetic resonance imaging, carries an adverse prognosis, it is likely that such new information will affect the chelating programme of patients. In these cases, there are a number of options available: (i) ongoing treatment with either desferrioxamine (DFO) or deferiprone may be intensified; (ii) the patient may be switched to the alternative chelator or (iii) combined chelation with both DFO and deferiprone may be started, which is more effective than using either chelator alone. For patients with symptomatic heart disease, continuous intravenous DFO with, or without deferiprone, remains the currently recommended treatment, in view of its documented ability to salvage these patients.

KW - Deferiprone

KW - Desferrioxamine

KW - Haemosiderosis

KW - Heart

KW - Iron chelation

UR - http://www.scopus.com/inward/record.url?scp=2942616383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942616383&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2004.04946.x

DO - 10.1111/j.1365-2141.2004.04946.x

M3 - Article

C2 - 15147368

AN - SCOPUS:2942616383

VL - 125

SP - 545

EP - 551

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -